|
KMID : 0880220220600030247
|
|
Journal of Microbiology
2022 Volume.60 No. 3 p.247 ~ p.254
|
|
|
Current status and perspectives on vaccine development against dengue virus infection
|
|
Park Ji-Sang
Kim Ju
Jang Yong-Suk
|
|
|
Abstract
|
|
|
|
Dengue virus (DENV) consists of four serotypes in the family Flaviviridae and is a causative agent of dengue fever, dengue hemorrhagic fever, and dengue shock syndrome. DENV is transmitted by mosquitoes, Aedes aegypti and A. albopictus, and is mainly observed in areas where vector mosquitoes live. The number of dengue cases reported by the World Health Organization increased more than 8-fold over the last two decades from 505,430 in 2000 to over 2.4 million in 2010 to 5.2 million in 2019. Although vaccine is the most effective method against DENV, only one commercialized vaccine exists, and it cannot be administered to children under 9 years of age. Currently, many researchers are working to resolve the various problems hindering the development of effective dengue vaccines; understanding of the viral antigen configuration would provide insight into the development of effective vaccines against DENV infection. In this review, the current status and perspectives on effective vaccine development for DENV are examined. In addition, a plausible direction for effective vaccine development against DENV is suggested.
|
|
|
KEYWORD
|
|
|
antibody-dependent enhancement, antigen, dengue virus, envelope, vaccine
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|